{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000088","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.728314+00:00","generated_at":"2026-05-16T14:53:12.985623+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"AEON Biopharma posts corporate presentation with biosimilar pipeline update","bullets":["Presentation dated December 2025 highlights fresh data and new capital for full-label biosimilar approval.","Company emphasizes simplified structure to accelerate development of lead molecule.","No specific clinical or financial figures were disclosed in the furnished presentation excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000088","json":"https://secwatch.observer/filing/0001837607-25-000088.json","markdown":"https://secwatch.observer/filing/0001837607-25-000088.md","text":"https://secwatch.observer/filing/0001837607-25-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000088/0001837607-25-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000088/aeon-20251204x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:53:12.985623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}